Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 986-993, 2009. First published March 19, 2009; 10.1373/clinchem.2008.113936
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.113936v1
55/5/986    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gensburger, O.
Right arrow Articles by Marquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gensburger, O.
Right arrow Articles by Marquet, P.
(Clinical Chemistry. 2009;55:986-993.)
© 2009 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase

Olivier Gensburger1,2, Nicolas Picard1,2,3 and Pierre Marquet1,2,3,a

1 INSERM UMR-S850, Limoges, France; 2 Université de Limoges, Faculté de Médecine, Limoges, France; 3 CHU Limoges, Service de Pharmacologie-Toxicologie, Limoges, France.

aAddress correspondence to this author at: INSERM UMR-S850, Faculté de Médecine, Laboratoire de Pharmacologie Médicale, 2 rue du Dr. Marcland, 87025 Limoges cedex, France. Fax +33 555 05 61 62; e-mail pierre.marquet{at}unilim.fr.

Background: The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation. We investigated the action of the MPA metabolites MPA-phenyl-glucuronide (MPAG) and MPA-acyl-glucuronide (AcMPAG) on recombinant human IMPDH II (rhIMPDH II), as well as their passage into lymphocytes in vitro.

Methods: We measured rhIMPDH II activity spectrophotometrically through the initial velocity of NADH formation, leading to the computation of the kinetic parameters Km, IC50, and Ki (Michaelis constant, half-maximal inhibition concentration, and inhibition constant). We measured intracellular and extracellular concentrations of MPA, MPAG, and AcMPAG after incubation of Jurkat lymphoma cells with each compound separately, using liquid chromatography–tandem mass spectrometry.

Results: MPA and AcMPAG showed an inhibition of rhIMPDH II (IC50 25.6 µg/L and 301.7 µg/L, respectively; the Ki of MPA for NAD and IMP was 50.8 and 57.7 nmol/L, respectively; and that of AcMPAG for NAD and IMP was 382.0 and 511.0 nmol/L. MPAG had no significant effect on the enzyme. AcMPAG apparently acts by the same uncompetitive inhibition mechanism as MPA, with a 12-fold higher IC50 and an 8–10 times higher Ki. When coincubated with MPA, AcMPAG activity was negligible at pharmacological concentrations. Furthermore, after 6-h incubation at their respective maximum concentration (Cmax), MPA was 10 times more concentrated in Jurkat cells than AcMPAG.

Conclusions: AcMPAG is a weaker inhibitor of rhIMPDH II than MPA and is less concentrated in lymphocytes in vitro, suggesting that it would not be pharmacologically active in vivo and might not need to be monitored in MPA-treated patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.